Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat—A Narrative Review
Journal of Clinical Medicine · 22.07.2026 · 15 (14) · 5749
DOI: 10.3390/jcm15145749 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.07.2026. Verfasst von Jacek Kubica und 9 weiteren Autor:innen. Beteiligte Einrichtung: Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Heart failure (HF) remains a major global health burden despite substantial therapeutic advances. Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, represents a distinct pharmacological strategy targeting impaired nitric oxide–sGC–cyclic guanosine monophosphate (NO–sGC–cGMP) signaling, a pathway closely linked to endothelial dysfunction, vascular stiffness, myocardial fibrosis, and adverse remodeling. This narrative review synthesizes the current evidence on the efficacy, safety, and clinical positioning of vericiguat across the heart failure spectrum, with a particular focus on worsening heart failure with reduced ejection fraction (HFrEF), while integrating recent trial data, updated guideline recommendations, and emerging real-world evidence to define its contemporary role in clinical practice. Randomized trials, subgroup analyses, and contemporary meta-analyses indicate that vericiguat provides a modest but clinically relevant reduction in HF-related outcomes, especially in high-risk patients with recent decompensation. However, its overall effect appears smaller than that of foundational therapies such as angiotensin receptor–neprilysin inhibitors and sodium–glucose cotransporter 2 inhibitors. Recently published data from the VICTOR program further refine the role of vericiguat in compensated outpatients with chronic HFrEF, showing a neutral primary outcome but providing supportive hypothesis-generating signals across a broader risk continuum while confirming a favorable safety profile. Overall, vericiguat should be regarded not as a replacement for cornerstone therapy but as a mechanistically complementary, risk-targeted adjunct for selected patients with persistent residual risk despite guideline-directed medical therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland.
- Modern Medical Technologies Center, 87-100 Torun, Poland.
- Gajda-Med District Hospital, 06-102 Pultusk, Poland.
- Institute of Medical Sciences, The John Paul II Catholic University of Lublin, 20-950 Lublin, Poland.
- Department of Life and Health Sciences, Link Campus University, 00165 Rome, Italy.
ORCID-Profile: Jacek Kubica, Aldona Kubica, Robert Gajda, Julia M Umińska, Jakub Ratajczak
Zitieren
APA
Kubica, J., Kubica, A., Gajda, R., Laskowska, E., Umińska, J. M., Ratajczak, J., Niezgoda, P., Mrzywka, N., Szarpak, Ł., & Navarese, E. P. (2026). Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat—A Narrative Review. Journal of Clinical Medicine, 15(14), 5749. https://doi.org/10.3390/jcm15145749
Vancouver
Kubica J, Kubica A, Gajda R, Laskowska E, Umińska JM, Ratajczak J, et al. Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat—A Narrative Review. Journal of Clinical Medicine. 2026;15(14):5749. doi:10.3390/jcm15145749
BibTeX
@article{Kubica2026,
author = {Kubica, Jacek and Kubica, Aldona and Gajda, Robert and Laskowska, Ewa and Umińska, Julia M and Ratajczak, Jakub and Niezgoda, Piotr and Mrzywka, Natalia and Szarpak, Łukasz and Navarese, Eliano P},
title = {Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat—A Narrative Review},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5749},
doi = {10.3390/jcm15145749}
}
EUVIMED